XNCR - XencorAbout Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
| Previous Close | $49.27 | Open | $49.64 |
| Volume | 89.7K | Market Cap | 1.788B |
| Yield | Last Dividend |
| Xencor, UCLA Ink Collaboration Pact For ... | 02/25/21 |
| Xencor Inc (NASDAQ: XNCR) and UCLA Technology Development Group have agreed to develop novel therapeutic antibodies utilizing Xencor???s modular suite... | |
| Xencor and UCLA Enter Collaboration to D... | 02/25/21 |
| ??? Collaboration joins together Xencor???s modular XmAb engineered protein platforms with UCLA???s expertise in biology to rapidly create and advance... | |
| The Daily Biotech Pulse: DermTech Soars ... | 02/11/21 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 11) 10X... | |
| The Daily Biotech Pulse: Lilly COVID-19 ... | 02/10/21 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 10) 9 M... | |
| Xencor to Present at Upcoming Investor C... | 02/04/21 |
| MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies ... | |
| Global Anti-CD19 Therapeutic Antibody Ma... | 01/25/21 |
| Databridgemarketresearch.com Present ???Anti-CD19 Therapeutic Antibody Market??? Industry Trends and Forecast to 2027??? new report to its research da... | |
| The Daily Biotech Pulse: Fluidigm's Sali... | 01/22/21 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 21) Aca... | |
| The Daily Biotech Pulse: GSK, Vir To Sta... | 01/12/21 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 11) 10X... | |
| The Daily Biotech Pulse: CureVac COVID-1... | 01/07/21 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 6) 9 ??... | |
| Xencor and MD Anderson Enter Strategic C... | 01/06/21 |
| Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and aut | |
| J&J taps the bispecific experts at Xenco... | 12/07/20 |
| J&J is trying something new for prostate cancer. Teaming up with Xencor, its Janssen subsidiary is looking to discover bispecific antibodies that grab... | |
| Mizuho Securities Stick to Their Buy Rat... | 12/06/20 |
| Mizuho Securities Stick to Their Buy Rating for Xencor Inc | |
| Xencor Presents Updated Data from the Ph... | 12/06/20 |
| MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies ... | |
| Global Bi Syndrome Treatment Market 2020... | 11/20/20 |
| This Bi Syndrome Treatment report provides complete analysis of the market on global and regional level. It inspects the development rate and the mark... | |
| Recent Updates on Anal Cancer Drug Marke... | 11/18/20 |
| Global Anal Cancer Drug Market report brings into light key market dynamics of the sector. It provides guidelines about planning of advertising and sa... | |
| Xencor to Present at Upcoming Investor C... | 11/12/20 |
| MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies ... | |
| Xencor, MorphoSys and Incyte Enter into ... | 11/11/20 |
| MONROVIA, Calif. & PLANEGG/MUNICH, Germany & WILMINGTON, Del.--(BUSINESS WIRE)--Xencor (NASDAQ: XNCR), MorphoSys AG (FSE: MOR; Prime Standard Segment,... | |
| RBC Capital Stick to Their Buy Rating fo... | 11/10/20 |
| RBC Capital Stick to Their Buy Rating for Xencor Inc | |
| Xencor Presents Data from Multiple Precl... | 11/09/20 |
| MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies ... | |
| The Week Ahead In Biotech: Supernus, San... | 11/08/20 |
| Biotech stocks turned around with the broader market in the week ended Nov. 6, as investors warmed to the idea of a split Congress and a change of gua... | |
| Xencor to Present Data from Phase 1 Stud... | 11/04/20 |
| MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies ... | |
| Xencor to Host Third Quarter 2020 Financ... | 10/29/20 |
| MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies... | |
| Xencor to Present Data from the Phase 1 ... | 10/14/20 |
| MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies ... | |
| Xencor and MD Anderson Enter Strategic C... | 09/03/20 |
| MONROVIA, Calif. & HOUSTON--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal a... | |
| Xencor to Present at Upcoming Investor C... | 08/05/20 |
| MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies ... | |
| Xencor Reports Second Quarter 2020 Finan... | 08/04/20 |
| MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies ... | |
| Xencor to Host Second Quarter 2020 Finan... | 07/28/20 |
| MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies... | |
| Atreca teams up with Xencor to develop T... | 07/08/20 |
| Atreca (NASDAQ:BCEL) is up 6% premarket after entering into a collaboration and license agreement with Xencor (NASDAQ:XNCR) to research, develop and c... | |
| Xencor Presents Data from Four Preclinic... | 06/22/20 |
| MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies... | |
| Applied BioMath, LLC Announces Two-year ... | 06/15/20 |
| CONCORD, Mass., June 15, 2020 /PRNewswire/ -- Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mecha... | |
| Strong Buy rating | 02/24/21 |
| Raymond James upgrades from Market Perform to Outperform rating and announces Price Target of $58.00 | |
| Date | 2021-02-23 (AMC) | Est. (EPS/Rev.) | ($0.38)/ 29.46M |
| Actual (EPS/Rev.) | $-0.24/ $41.85 M | EPS (TTM) | 0 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
